Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. 

Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.

Health Care

Nuclear

Orano Med

Julien Dodet

Virgil Dodson

Sadaf Qureshi

Michael Courtney

Haley Lozano-Sprague

Carter Rose

Allison Manuel

Julien Torgue

Nicolas Bozovic

Gwenaelle Nourry

Pascal Mirocha

J. Robert Chastain (Rob)

The Quality Assurance and Control Team at Orano Med ensures the integrity, safety, and efficacy of high-purity lead-212 production processes and related products. This team oversees rigorous testing, adherence to regulatory standards, and continuous process improvement to support Orano Med’s innovative targeted alpha therapy (TAT) projects aimed at combating cancer. Their work involves detailed analysis, quality checks, and compliance assurance to maintain the highest standards in nuclear medicine technology.

Quality Assurance and Control Team

Production and Operations

Engineering and Technical Team

Quality Assurance and Control Team

About

Team members

Other teams at Orano Med

Production and Operations

Engineering and Technical Team